These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37197312)

  • 21. A decision-theoretic phase I-II design for ordinal outcomes in two cycles.
    Lee J; Thall PF; Ji Y; Müller P
    Biostatistics; 2016 Apr; 17(2):304-19. PubMed ID: 26553915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):. PubMed ID: 25485277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials.
    Thall PF
    JCO Precis Oncol; 2019; 3():. PubMed ID: 33015521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
    Zhao L; Taylor JM; Schuetze SM
    Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A curve free Bayesian decision-theoretic design for phase Ia/Ib trials considering both safety and efficacy outcomes.
    Fan S; Lee BL; Lu Y
    Stat Biosci; 2020 Jul; 12(2):146-166. PubMed ID: 33815623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision rules for subgroup selection based on a predictive biomarker.
    Krisam J; Kieser M
    J Biopharm Stat; 2014; 24(1):188-202. PubMed ID: 24392985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.
    Antoniou M; Jorgensen AL; Kolamunnage-Dona R
    J Pers Med; 2017 Dec; 7(4):. PubMed ID: 29207572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Centered Clinical Trial Design for Heart Failure Devices via Bayesian Decision Analysis.
    Chaudhuri SE; Adamson P; Bruhn-Ding D; Ben Chaouch Z; Gebben D; Rincon-Gonzalez L; Liden B; Reed SD; Saha A; Schaber D; Stein K; Tarver ME; Lo AW
    Patient; 2023 Jul; 16(4):359-369. PubMed ID: 37076697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian enrichment strategies for randomized discontinuation trials.
    Trippa L; Rosner GL; Müller P
    Biometrics; 2012 Mar; 68(1):203-11. PubMed ID: 21714780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.